NCT07659925 Periodization-Based Strength Exercise Training in İndividuals With Type 2 Diabetes
| NCT ID | NCT07659925 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Baskent University |
| Condition | Type 2 Diabetes |
| Study Type | INTERVENTIONAL |
| Enrollment | 48 participants |
| Start Date | 2026-05-01 |
| Primary Completion | 2026-11 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 48 participants in total. It began in 2026-05-01 with a primary completion date of 2026-11.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This randomized controlled study aims to compare the effects of different periodization-based strength training approaches in individuals with type 2 diabetes mellitus. Participants will be allocated to non-linear periodization, linear periodization, or control groups. The intervention program will be conducted for 8 weeks and will evaluate exercise capacity, muscle strength, quality of life, body composition, and metabolic parameters.
Eligibility Criteria
Inclusion Criteria: * Adults aged between 18 to 65 years * Diagnosis of Type 2 Diabetes Mellitus (T2DM) * Not having participated in any structured exercise program within the last 6 months * Willingness to participate in the study and provide written informed consent Exclusion Criteria: * Presence of nephropathy, retinopathy, or peripheral neuropathy * Presence of neurological, cognitive, or orthopedic disorders that may affect outcome measurements * Severe respiratory disease (Forced Expiratory Volume in the first second \[FEV1\] \<35% or Forced Vital Capacity \[FVC\] \<50%) * Presence of ischemic heart disease or peripheral arterial disease * History of any cardiovascular event within the last 6 months * Current malignancy
Contact & Investigator
Neslihan Duruturk, PhD
PRINCIPAL INVESTIGATOR
Baskent University
Frequently Asked Questions
Who can join the NCT07659925 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Type 2 Diabetes. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07659925 currently recruiting?
Yes, NCT07659925 is actively recruiting participants. Contact the research team at erkcaysegl@gmail.com for enrollment information.
Where is the NCT07659925 trial being conducted?
This trial is being conducted at Ankara, Turkey (Türkiye).
Who is sponsoring the NCT07659925 clinical trial?
NCT07659925 is sponsored by Baskent University. The principal investigator is Neslihan Duruturk, PhD at Baskent University. The trial plans to enroll 48 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.